VALN (VALN) revenue breakdown
By segment, COVID is the largest at 77% of fiscal 2022 revenue, growing 22% a year over 1 years.
By product, COVID VLA2001 is the largest at 76% of fiscal 2022 revenue; Third party products grew fastest, 153% a year over 2 years.
Revenue by segment
Fiscal years, as VALN reports them in its 10-K filings; fiscal 2022 total $400M.
| Segments | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|
| COVID | — | $253M | $310M | 77% |
| Commercialized products | $66M | $63M | $85M | 21% |
| Vaccine candidates | $32M | $3M | $6M | 1% |
| Technologies and services | $12M | $29M | -$39M | -10% |
Revenue by product
Fiscal years, as VALN reports them in its 10-K filings; fiscal 2022 total $406M.
| Products | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|
| COVID VLA2001 | — | — | $253M | $310M | 76% |
| IXIARO® | — | $48M | $45M | $41M | 10% |
| Third party products | — | $4M | $15M | $27M | 7% |
| DUKORAL® | — | $13M | $2M | $17M | 4% |
| Chikungunya VLA1553 | -$11M | — | $3M | $6M | 1% |
| Services related to clinical trial material | — | $8M | $10M | $3M | 1% |
| Others | — | $4M | $3M | $3M | 1% |
| Commercialized products | $130M | — | — | — | — |
| Technologies and services | $6M | — | — | — | — |
| Lyme VLA15 | — | $32M | $14M | -$46M | -11% |
Revenue by region
Fiscal years, as VALN reports them in its 10-K filings; fiscal 2025 total $175M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| United States | $64M | $68M | $55M | -$24M | $33M | $49M | $54M | 31% |
| Canada | $24M | $9M | $4M | $19M | $28M | $32M | $30M | 17% |
| Germany | $10M | $7M | $966,000 | $69M | $14M | $18M | $17M | 10% |
| France | — | $2M | $1M | $47M | $6M | $7M | $15M | 8% |
| Nordics | $11M | $3M | $2M | $12M | $13M | $14M | $14M | 8% |
| Other Europe | -$5M | $3M | $5M | $19M | $9M | $9M | $14M | 8% |
| United Kingdom | $9M | $3M | $256M | $181M | $20M | $19M | $13M | 7% |
| Austria | $7M | $10M | $19M | $22M | $15M | $16M | $9M | 5% |
| Rest of World | $5M | $4M | $5M | $17M | $16M | $5M | $9M | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VALN.
Open VALN in InvestinglyQuestions
Where does VALN make its money?
In fiscal 2022, by segment: COVID $310M, Commercialized products $85M, Vaccine candidates $6M, Technologies and services -$39M.
From VALN's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.